Therapeutic efficacy of danazol in myelodysplastic syndromes
article
OA: closed
CC0
⤵ 8 in-corpus citations
Limited metadata. Only one source feed has indexed
this record so far — no abstract, full text, or open-access copy is
available through Endo Lab. The
publisher's page (linked below)
is the canonical location for the actual content. If you have institutional
access, use "Find at my library".
AI-generated summary
This paper investigates the therapeutic efficacy of danazol in patients with myelodysplastic syndromes, detailing its effects and outcomes.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (20)
- Danazol via openalex
- Danazol and Myelodysplasic Syndromes via openalex
- Danazol binds to progesterone receptors and inhibits the growth of human endometrial cancer cells in vitro via openalex
- Danazol in the treatment of myelodysplastic syndromes via openalex
- Danazol Therapy in Acquired Idiopathic Sideroblastic Anemia via openalex
- Efficacy of danazol in pure red cell aplasia via openalex
- Erythrocytosis induced by danazol in an anephric patient. via openalex
- doi:10.1111/j.1365-2141.1976.tb03563.x via openalex
- W2412335873 via openalex
- W2434609641 via openalex
- W6714487862 via openalex
- W6715301591 via openalex
- doi:10.1111/j.1365-2141.1982.tb08475.x via openalex
- W6718373470 via openalex
- doi:10.1111/j.1600-0609.1986.tb00856.x via openalex
- doi:10.1016/s0140-6736(87)91077-4 via openalex
- doi:10.7326/0003-4819-103-1-58 via openalex
- doi:10.1111/j.1365-2141.1986.tb07544.x via openalex
- doi:10.1016/0002-9343(86)90677-7 via openalex
- doi:10.1182/blood.v30.3.352.352 via openalex
Cited by (8)
- Danazol for the Treatment of Myelodysplastic Syndromes: A Systematic Review 2023
- Danazol for the Treatment of Myelodysplastic Syndromes: A Systematic Review 2023
- Anabolic steroids in myelodysplastic syndromes: A systematic review 2020
- Danazol as First-Line Therapy for Myelodysplastic Syndrome 2017
- Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndrome 2002
- Prolonged complete remission of myelodysplastic syndrome treated with danazol, retinoic acid and low-dose prednisone 2000
- A review of 76 patients with myelodysplastic syndromes treated with danazol 1995
- A review of 76 patients with myelodysplastic syndromes treated with danazol 1994
Source provenance
- openalex
- last seen: 2026-05-11T06:24:00.257642+00:00
License: CC0
· commercial use OK